2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
April 17, 2018
By: Ross Blau
Westlaw Journal
Ross Blau co-authored, "2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways" with Jonathan Harris and Drew Hillier which was published by Westlaw Journal Medical Devices, Westlaw Journal Products Liability, Westlaw Journal Health Law, Westlaw Journal Pharmaceutical and Westlaw Journal Intellectual Property. The article discusses nuanced shifts in Federal Circuit opinions and the lessons that can be gleaned from them.
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
The DOJ’s Antitrust Whistleblower Rewards Program
Webinar
Antitrust
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
ABA 2026 Antitrust Global Seminar Series
Speaking Engagement
Antitrust
Do I Really Need To File? HSR Avoidance and the Edwards/Genesis Settlement
Podcast
Antitrust
Axinn Attorneys Earn Top Honors in Best Lawyers 2027
News
Antitrust
